Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1973 Jun;14(6):451-6.
doi: 10.1136/gut.14.6.451.

Serum complement in chronic liver disease

Serum complement in chronic liver disease

B J Potter et al. Gut. 1973 Jun.

Abstract

Total serum haemolytic complement activity (CH(50)) and the serum concentrations of both the third and fourth components of the complement system (C3 and C4) have been measured in 29 control subjects, 92 patients with chronic hepatocellular disease, and eight patients with large duct biliary tract obstruction. The mean C4 concentration was reduced in all types of chronic liver disease studied. However, the mean CH(50) and C3 values were increased in compensated primary biliary cirrhosis, were relatively normal in non-cirrhotic chronic active hepatitis, and were decreased in cryptogenic cirrhosis, particularly when ascites was present. There was a significant correlation between CH(50) and C3 in patients with chronic liver disease but no correlation between CH(50) and C4 or between C3 and C4. Raised values for CH(50) and C3 in primary biliary cirrhosis may be due at least in part to concomitant cholestasis since these values tend to be raised in patients with large duct biliary tract obstruction. Although primary biliary cirrhosis, chronic active hepatitis, and cryptogenic cirrhosis are considered to be part of a spectrum of chronic liver disease associated with disturbed immunity, the results of this study emphasize that there are clearly definable differences between these diseases in terms of the pattern of changes in serum complement.

PubMed Disclaimer

References

    1. J Immunol. 1970 Aug;105(2):279-90 - PubMed
    1. Clin Exp Immunol. 1972 Jul;11(3):311-20 - PubMed
    1. J Clin Invest. 1964 Aug;43:1507-17 - PubMed
    1. Science. 1969 Jan 17;163(3864):286-8 - PubMed
    1. J Exp Med. 1970 Oct 1;132(4):775-93 - PubMed

MeSH terms

Substances

LinkOut - more resources